Contents

Ranibizumab Therapy for Diabetic Macular Edema (RISE AND RIDE)

October 1, 2013

Clinical trial

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ.

Ophthalmology. 2013 Oct;120(10):2013-22.
Full text | Metrics.

Main finding: Ranibizumab rapidly and sustainably improved vision and reduced risk of further vision loss in patients with DME, with low rates of ocular and non-ocular harm.

 

  • Purpose: To evaluate the efficacy and safety of intravitreal ranibizumab in diabetic macular edema,
  • Study type: Randomized controlled trial
  • Condition: Diabetic Macular Edema

Participants: Type 1 or 2 DM, Ci-DME , VA 20/40-20/320 (6/12-6/96) and central subfield thickness ≥275 μm

 

  • n=377 (RISE), 382 (RIDE)

 

Intervention:

 

Groups:

 

  • Group 1: Sham
  • Group 2: Ranibizumab 0.3mg
  • Group 3: Ranibizumab 0.5mg
Outcome Groups Sham RAN 0.3mg RAN 0.5mg
Gain of ≥15 letters (Proportion) at 2 years RISE 18.1% 44.8% 39.2%
RIDE 12.3% 33.6% 45.7%
Gain of ≥15 letters (Proportion) at 3 years RISE 19.2% 36.8% 40.2%
RIDE 22.0% 51.2% 41.6%

April 1, 2012

Clinical trial

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS.

Ophthalmology. 2012 Apr;119(4):789-801.
Full text | Metrics.

Main finding: Ranibizumab rapidly and sustainably improved vision and reduced risk of further vision loss in patients with DME, with low rates of ocular and non-ocular harm.

 

  • Purpose: To evaluate the efficacy and safety of intravitreal ranibizumab in diabetic macular edema,
  • Study type: Randomized controlled trial
  • Condition: Diabetic Macular Edema

Participants: Type 1 or 2 DM, Ci-DME , VA 20/40-20/320 (6/12-6/96) and central subfield thickness ≥275 μm

 

  • n=377 (RISE), 382 (RIDE)

 

Intervention:

 

Groups:

 

  • Group 1: Sham
  • Group 2: Ranibizumab 0.3mg
  • Group 3: Ranibizumab 0.5mg
Outcome Groups Sham RAN 0.3mg RAN 0.5mg
Gain of ≥15 letters (Proportion) at 2 years RISE 18.1% 44.8% 39.2%
RIDE 12.3% 33.6% 45.7%
Gain of ≥15 letters (Proportion) at 3 years RISE 19.2% 36.8% 40.2%
RIDE 22.0% 51.2% 41.6%

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed